Cerebral Autoregulation Guiding Blood Pressure Management After Revascularization

Phase 2

Not yet recruiting

• Conditions: Cerebrovascular Insufficiency; Individuation; Cerebral Autoregulation; Blood Pressure; Hemorrhagic Transformation Due to Acute Stroke; Ischemic Stroke; Revascularization
• Interventions: Drug: Hypotensive Drugs and/or Vasoactive Drugs

• Registration Number: NCT05670028
• Lead Sponsor: Beijing Tiantan Hospital

Brief Summary

This clinical trial aims to learn whether blood pressure (BP) guided by individualized cerebral autoregulation (CA) is safe and provides a better prognosis than a fixed target in patients with ischemic stroke after endovascular therapy. The BP of participants will be managed at least 48 hours after revascularization. Researchers will compare the CA-guided BP group with the fixed target BP group to mainly see if individualized BP could help more patients to have their neurological function improved at seven days.

Detailed Description

Not available

Study Timeline

• Status Verified: 2023-01
• Study First Submitted: 2023-01-02
• Study First Submitted QC: 2023-01-02
• Study First Posted: 2023-01-04
• Last Update Submitted: 2023-01-04
• Last Update Posted: 2023-01-05
• Study Start: 2023-06-04
• Primary Completion: 2026-01-31
• Study Completion: 2026-06-04

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Acute ischemic stroke, undergone endovascular treatment within 24 hours of onset (time of stroke is the last known normal for wake-up stroke or with unknown onset time), with reaching the goal of mTICI grade 2b-3
• No functional disability before stroke (mRS 0-1)
• Angiography (CTA, MRA or DSA) before endovascular therapy confirmed occlusion of the internal carotid artery and/or the middle cerebral artery M1 to M2 segment, with consistent clinical symptoms.
• Informed consent is given by the patient or the legal representative.

Exclusion Criteria

• Hemorrhagic transformation with mass effect (PH-2 type parenchymal hematoma) occurs during the operation.
• Coma, dilated pupils on one or both sides, dull or absent light reflex is noticed before randomization
• Dissection of aorta, common carotid artery, internal carotid artery, subclavian artery, intracranial artery; severe bilateral subclavian artery stenosis; contraindications of radial artery puncture were found before or during surgery.
• Shock.
• Severe cardiomyopathy with heart failure (EGFR ≤ 30% or NYHA Grade IV), acute myocardial infarction, or unstable angina.
• Possible infective endocarditis, infective embolism, or vasculitis.
• Participating in other clinical research involving drug or device intervention after endovascular therapy.
• Women who plan or are pregnant, or breastfeeding.
• Severe liver or kidney disease, malignant tumor with a life expectancy is less than 3 months.
• The 90-day follow-up is not expected to be completed.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Fixed target BP	Hypotensive Drugs and/or Vasoactive Drugs	After randomization to 48h after endovascular therapy, the target of BP was determined by clinicians according to current guidelines, i.e. \<180/105mmHg.
CA-guided BP	Hypotensive Drugs and/or Vasoactive Drugs	The upper and lower limits of autoregulation determined by ICM+ software are used to guide the range of blood pressure control, but no more than 40% above or below the usual BP. From when the upper or lower limit of autoregulation appeared in ICM+ software to 48h after revascularization, the total time of actual BP beyond the CA range will be no more than two hours through drug intervention.

Primary Outcome Measures

Name	Time	Method
Early neurological recovery	Seven days after endovascular therapy (or on the discharge if less than seven days)	the NIHSS score decreased by ≥ 4 from the preoperative baseline

Secondary Outcome Measures

Name	Time	Method
Infarct volume growth	Seven days after endovascular therapy (or on the discharge if less than seven days)	The infarct volume at the preoperative baseline is defined as the area with rCBF\<30% or ADC\<620mm×10\^-6mm\^2/s via RAPID software and that at seven days is measured manually on brain CT.
Distribution of modified Rankin Scale scores ranging from 0-6	90 days after endovascular therapy	To compare the difference in the distribution of mRS scores. The Modified Rankin Scale (mRS) is a disability scale with possible scores ranging from 0 (no residual symptoms) to 6 (dead).
The proportion of functional independence with modified Rankin Scale scores 0-2	90 days after endovascular therapy	The Modified Rankin Scale (mRS) is a disability scale with possible scores ranging from 0 (no residual symptoms) to 6 (dead).